Phase III trials in retinal biosimilars: parity before pragmatism

Eye 2026 Open access

Read full text

Authors: Jay Umed Sheth

DOI: 10.1038/s41433-026-04718-4

Cited by: 1

References: 1

Fields of Study & Subjects

Retinal Diseases and Treatments Biosimilars and Bioanalytical Methods Drug-Induced Ocular Toxicity

References 1